CDK2 and glioblastoma: In glioblastoma cells, mdig knockdown by shRNAs not only increased levels of H3K9me3 but also inhibited expression of several cell cycle regulatory proteins, such as cyclin B, cyclin D1, CDK1, CDK2, etc.25 Similarly, mdig appears to be highly capable of reducing levels of H3K9me3 in human hepatocellular carcinoma (HCC).26 Increased expression of mdig was observed in approximately 70% of HCC samples collected from 155 patients.